Surveillance of Patients With Adenocarcinoma of the Gastroesophageal Junction or Esophagus

Inclusion Criteria: * Adenocarcinoma of esophagus or gastroesophageal junction (nidus of the cancer within 5 cm from the gastroesophageal junction) confirmed by biopsy with clinical stage I, II, or III. The superficial adenocarcinoma of the esophagus will be excluded. * Received no previous treatment for esophageal cancer. * Measurable or evaluable disease * ECOG performance status: 0 to 2 that is able to perform activities of daily living with minimal assistance * Adequate bone marrow function (hemoglobulin ≥8 g/dl, neutrophil ≥1.5x109/L and platelet ( ≥100x109/L) * Adequate liver function * Bilirubin normal, Meets 1 of the following criteria: * Alkaline phosphatase (AP) normal AND AST/ALT ≤ 5 times upper limit of normal (ULN) * AP ≤ 2.5 times ULN AND AST/ALT ≤ 1.5 times ULN * AP ≤ 5 times ULN AND AST/ALT normal * Adequate kidney function (creatinine ≤1.5 UNL and creatinine clearance ≥ 60 ) * Be at least 4 weeks from recent major surgical procedures. * Patients must be able to understand the nature of the study and give written informed consent * At least one measurable lesion on CT, MRI or esophageal barium exam. Exclusion Criteria: * Age \< 18 years and \>80 years * Contraindication for irradiation: complete obstruction of esophagus, deep esophageal ulcer, fistula to mediastinum, or hematemesis * Participating in other clinical trials * Pregnancy * Clinically significant and uncontrolled major medical conditions including but not limited to active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation that would limit compliance with study requirements * any medical condition, which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities